Behind the $2.5 Billion AI Drug Discovery Partnership, Neuroimmune Therapies Still Come Back to Human Evidence
Insilico and SK Biopharmaceuticals are pushing AI drug discovery toward the intersection of neurology and immunology, but beyond the contract ceiling and space-style ambitions, what can truly change patients’ lives remains reproducible, regulatable, and clinically validated biological evidence.